SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH M impact

FDA Issues Complete Response Letter for Capricor’s Deramiocel BLA

The FDA issued a complete response letter to Capricor for its Deramiocel biologics license application for Duchenne muscular dystrophy.

CAPR

Story updates

11:44:28 PM UTC
SquawkNews
UPDATE 1-US FDA declines to approve Capricor's cell therapy for Duchenne muscular dystrophy; shares

Related stories